Tetrahydro-β-carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications

• DOI: 10.1039/c5tb01930c
• Publication Date: 2015-12-18T09:34:55Z
• Authors: Xi Hu; Ming Zhao; Yuji Wang; Yaonan Wang; Shurui Zhao; Jianhui Wu; Xiangmin Li; Shiqi Peng
• Keywords: Thymopentin; Conjugate

To improve the therapeutic efficacy of cancer patients a novel conjugate thymopentin (TP5) and (1S,3S)-1-methyl-tetrahydro-β-carboline-3-carboxylic acid (MTC) was presented. In water mouse plasma MTCTP5 forms nanoparticles 14-139 nm in diameter, suitable size for delivery blood circulation. releases MTC, while presence trypsin MTC TP5. On rat models dose dependently slows down tumor growth, inhibits inflammatory response blocks thrombosis. The anti-tumor activity as well anti-inflammation anti-thrombotic are 100 fold 10 higher than those respectively, which attributed to fact that it down-regulates levels TNF-α IL-8 treated animals. immunology enhancing activities vitro vivo similar TP5, is up-regulates IL-2 CD4 level CD8 alanine transaminase, aspartate transaminase creatinine assays indicate therapy does not injure liver kidney survival time mice significantly longer TP5 mice.